Russia is obviously not a big market for Relenza or we would see it in the royalties. This means they have been using Tamiflu and just hoping it keeps working. So Roche will get a bit less cream but sales will possibly be not too much changed.
Finally all will need Relenza. From Biota's perspective the date of that need would preferably be prior to patent expiry.
